These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 24571723)

  • 1. The calculus of cures.
    Kocher R; Roberts B
    N Engl J Med; 2014 Apr; 370(16):1473-5. PubMed ID: 24571723
    [No Abstract]   [Full Text] [Related]  

  • 2. The $2.6 billion pill--methodologic and policy considerations.
    Avorn J
    N Engl J Med; 2015 May; 372(20):1877-9. PubMed ID: 25970049
    [No Abstract]   [Full Text] [Related]  

  • 3. Drug development costs when financial risk is measured using the Fama-French three-factor model.
    Vernon JA; Golec JH; Dimasi JA
    Health Econ; 2010 Aug; 19(8):1002-5. PubMed ID: 19655335
    [TBL] [Abstract][Full Text] [Related]  

  • 4. We Can use Market Forces to Moderate Drug Prices.
    Miller HI
    Mo Med; 2019; 116(6):451-453. PubMed ID: 31911716
    [No Abstract]   [Full Text] [Related]  

  • 5. Costing drug development.
    Nat Rev Drug Discov; 2003 Apr; 2(4):247. PubMed ID: 12680358
    [No Abstract]   [Full Text] [Related]  

  • 6. [Development of new drugs is too expensive].
    Andreasen J
    Ugeskr Laeger; 2003 May; 165(19):1959-60. PubMed ID: 12795066
    [No Abstract]   [Full Text] [Related]  

  • 7. New estimates of drug development costs.
    Frank RG
    J Health Econ; 2003 Mar; 22(2):325-30. PubMed ID: 12606149
    [No Abstract]   [Full Text] [Related]  

  • 8. [Systematic off-label use of drugs].
    Høeg E; Frostelid T
    Tidsskr Nor Laegeforen; 2010 Aug; 130(15):1452-3. PubMed ID: 20706302
    [No Abstract]   [Full Text] [Related]  

  • 9. Inadequately met needs.
    Nat Biotechnol; 2011 May; 29(5):371. PubMed ID: 21552219
    [No Abstract]   [Full Text] [Related]  

  • 10. Rising costs hold up drug discovery.
    Miller HI
    Nature; 1998 Oct; 395(6705):835. PubMed ID: 9804407
    [No Abstract]   [Full Text] [Related]  

  • 11. A cheat sheet to navigate the complex maze of exclusivities in the United States.
    Peng B; Tomas MC
    Pharm Pat Anal; 2014 Jul; 3(4):339-43. PubMed ID: 25291306
    [No Abstract]   [Full Text] [Related]  

  • 12. The art of the alliance.
    Menzel GE; Xanthopoulos KG
    Nat Biotechnol; 2012 Apr; 30(4):313-5. PubMed ID: 22491275
    [No Abstract]   [Full Text] [Related]  

  • 13. Health, Wealth, and the 21st Century Cures Act.
    Lo AW; Philipson TJ; von Eschenbach AC
    JAMA Oncol; 2016 Jan; 2(1):17-8. PubMed ID: 26513279
    [No Abstract]   [Full Text] [Related]  

  • 14. Who pays what in drug development.
    Love J
    Nature; 1999 Jan; 397(6716):202. PubMed ID: 9930689
    [No Abstract]   [Full Text] [Related]  

  • 15. US signs contract with ZMapp maker to accelerate development of the Ebola drug.
    McCarthy M
    BMJ; 2014 Sep; 349():g5488. PubMed ID: 25189475
    [No Abstract]   [Full Text] [Related]  

  • 16. Generic drugs: the stalling game.
    Consum Rep; 2001 Jul; 66(7):36-40. PubMed ID: 11725791
    [TBL] [Abstract][Full Text] [Related]  

  • 17. America's other drug problem: how the drug industry distorts medicine and politics.
    Relman AS; Angell M
    New Repub; 2002 Dec; 227(25):27-41. PubMed ID: 12561803
    [No Abstract]   [Full Text] [Related]  

  • 18. Drug and vaccine development for infectious diseases: the value of priority review vouchers.
    Matheny J; Smith B; Courtney B; Mair M
    Clin Pharmacol Ther; 2009 Jun; 85(6):571-2. PubMed ID: 19451907
    [No Abstract]   [Full Text] [Related]  

  • 19. The drug that could have been.
    Schultz S
    US News World Rep; 2002 Aug; 133(7):18, 20-3. PubMed ID: 12195678
    [No Abstract]   [Full Text] [Related]  

  • 20. Realizing two-tiered innovation policy through drug regulation.
    Ridgway WE
    Stanford Law Rev; 2006 Feb; 58(4):1221-50. PubMed ID: 16685807
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.